Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 111


Epstein-Barr Virus MicroRNA Expression Increases Aggressiveness of Solid Malignancies.

Pandya D, Mariani M, He S, Andreoli M, Spennato M, Dowell-Martino C, Fiedler P, Ferlini C.

PLoS One. 2015 Sep 16;10(9):e0136058. doi: 10.1371/journal.pone.0136058. eCollection 2015.


Nek6 and Hif-1α cooperate with the cytoskeletal gateway of drug resistance to drive outcome in serous ovarian cancer.

Donato MD, Fanelli M, Mariani M, Raspaglio G, Pandya D, He S, Fiedler P, Petrillo M, Scambia G, Ferlini C.

Am J Cancer Res. 2015 May 15;5(6):1862-77. eCollection 2015.


Defining "mutation" and "polymorphism" in the era of personal genomics.

Karki R, Pandya D, Elston RC, Ferlini C.

BMC Med Genomics. 2015 Jul 15;8:37. doi: 10.1186/s12920-015-0115-z.


Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer.

Prislei S, Martinelli E, Zannoni GF, Petrillo M, Filippetti F, Mariani M, Mozzetti S, Raspaglio G, Scambia G, Ferlini C.

Oncotarget. 2015 Aug 7;6(22):18966-79.


Cyparissins A and B, jatrophane diterpenes from Euphorbia cyparissias as Pgp inhibitors and cytotoxic agents against ovarian cancer cell lines.

Lanzotti V, Barile E, Scambia G, Ferlini C.

Fitoterapia. 2015 Jul;104:75-9. doi: 10.1016/j.fitote.2015.05.012. Epub 2015 May 20.


From Protein Communication to Drug Discovery.

Persico M, Di Dato A, Orteca N, Fattorusso C, Novellino E, Andreoli M, Ferlini C.

Curr Top Med Chem. 2015;15(20):2019-31.


Class III β-tubulin in normal and cancer tissues.

Mariani M, Karki R, Spennato M, Pandya D, He S, Andreoli M, Fiedler P, Ferlini C.

Gene. 2015 Jun 1;563(2):109-14. doi: 10.1016/j.gene.2015.03.061. Epub 2015 Apr 1. Review.


Herpes virus microRNA expression and significance in serous ovarian cancer.

Pandya D, Mariani M, McHugh M, Andreoli M, Sieber S, He S, Dowell-Martino C, Fiedler P, Scambia G, Ferlini C.

PLoS One. 2014 Dec 8;9(12):e114750. doi: 10.1371/journal.pone.0114750. eCollection 2014.


Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells.

Andreoli M, Persico M, Kumar A, Orteca N, Kumar V, Pepe A, Mahalingam S, Alegria AE, Petrella L, Sevciunaite L, Camperchioli A, Mariani M, Di Dato A, Novellino E, Scambia G, Malhotra SV, Ferlini C, Fattorusso C.

J Med Chem. 2014 Oct 9;57(19):7916-32. doi: 10.1021/jm5009902. Epub 2014 Sep 26.


GTP is an allosteric modulator of the interaction between the guanylate-binding protein 1 and the prosurvival kinase PIM1.

Persico M, Petrella L, Orteca N, Di Dato A, Mariani M, Andreoli M, De Donato M, Scambia G, Novellino E, Ferlini C, Fattorusso C.

Eur J Med Chem. 2015 Feb 16;91:132-44. doi: 10.1016/j.ejmech.2014.07.093. Epub 2014 Jul 27.


Integrated multidimensional analysis is required for accurate prognostic biomarkers in colorectal cancer.

Mariani M, He S, McHugh M, Andreoli M, Pandya D, Sieber S, Wu Z, Fiedler P, Shahabi S, Ferlini C.

PLoS One. 2014 Jul 2;9(7):e101065. doi: 10.1371/journal.pone.0101065. eCollection 2014.


HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer.

Mariani M, McHugh M, Petrillo M, Sieber S, He S, Andreoli M, Wu Z, Fiedler P, Scambia G, Shahabi S, Ferlini C.

Oncotarget. 2014 Jul 15;5(13):4855-67.


Sox9 and Hif-2α regulate TUBB3 gene expression and affect ovarian cancer aggressiveness.

Raspaglio G, Petrillo M, Martinelli E, Li Puma DD, Mariani M, De Donato M, Filippetti F, Mozzetti S, Prislei S, Zannoni GF, Scambia G, Ferlini C.

Gene. 2014 Jun 1;542(2):173-81. doi: 10.1016/j.gene.2014.03.037. Epub 2014 Mar 21.


Free testosterone drives cancer aggressiveness: evidence from US population studies.

Shahabi S, He S, Kopf M, Mariani M, Petrini J, Scambia G, Ferlini C.

PLoS One. 2013 Apr 24;8(4):e61955. doi: 10.1371/journal.pone.0061955. Print 2013.


MiR-200c and HuR in ovarian cancer.

Prislei S, Martinelli E, Mariani M, Raspaglio G, Sieber S, Ferrandina G, Shahabi S, Scambia G, Ferlini C.

BMC Cancer. 2013 Feb 8;13:72. doi: 10.1186/1471-2407-13-72.


βIII-Tubulin: biomarker of taxane resistance or drug target?

Karki R, Mariani M, Andreoli M, He S, Scambia G, Shahabi S, Ferlini C.

Expert Opin Ther Targets. 2013 Apr;17(4):461-72. doi: 10.1517/14728222.2013.766170. Epub 2013 Feb 2. Review.


Gli family transcription factors are drivers of patupilone resistance in ovarian cancer.

Mozzetti S, Martinelli E, Raspaglio G, Prislei S, De Donato M, Filippetti F, Shahabi S, Scambia G, Ferlini C.

Biochem Pharmacol. 2012 Dec 1;84(11):1409-18. doi: 10.1016/j.bcp.2012.08.019. Epub 2012 Sep 1.


Adrenomedullin in ovarian cancer: foe in vitro and friend in vivo?

Baranello C, Mariani M, Andreoli M, Fanelli M, Martinelli E, Ferrandina G, Scambia G, Shahabi S, Ferlini C.

PLoS One. 2012;7(7):e40678. doi: 10.1371/journal.pone.0040678. Epub 2012 Jul 30.


Gender influences the class III and V β-tubulin ability to predict poor outcome in colorectal cancer.

Mariani M, Zannoni GF, Sioletic S, Sieber S, Martino C, Martinelli E, Coco C, Scambia G, Shahabi S, Ferlini C.

Clin Cancer Res. 2012 May 15;18(10):2964-75. doi: 10.1158/1078-0432.CCR-11-2318. Epub 2012 Mar 21.


Novel drugs targeting microtubules: the role of epothilones.

Ferrandina G, Mariani M, Andreoli M, Shahabi S, Scambia G, Ferlini C.

Curr Pharm Des. 2012;18(19):2793-803. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk